On the Future of Psychedelic Assisted Therapy [ONLINE]
October 23 @ 7:00 pm - 8:30 pm
About this Event
Psychedelic assisted psychotherapy is on track to be the next breakthrough in mental health care. The last decade has seen a renaissance in the field of psychedelic science—moving it from the fringes of the scientific world to the mainstream with startling speed, legitimizing the medical potential of psychedelic drugs. Within the next decade, we are likely to have multiple psychedelic-assisted therapies approved in the US, Europe, and in many countries around the world for the treatment of various mental health conditions. As psychedelic therapy treatment success stories continue to emerge, and new scientific evidence from clinical trials show positive results, more patients will be asking for these treatments. In the coming years, we could see psychedelic therapy used in new treatment centers, psychiatric hospitals, privately owned clinics, as well as with independent practitioners.
Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS) has been a relentless advocate for developing legal contexts for the beneficial uses of psychedelics for decades and continues to be at the forefront of psychedelic-assisted treatment of PTSD, depression, and mental illness.
Join Rick for a fascinating conversation on the future of psychedelic assisted psychotherapy. Diving into his vast knowledge of the science of psychedelics, Rick discusses how drugs like LSD, psilocybin and MDMA affect your brain. He shares how, when paired with psychotherapy, psychedelics could change the way we treat PTSD, depression, substance abuse, and more.
Discover what the future holds for psychedelic assisted psychotherapy and the treatment of mental health.
Please note that this talk/conversation will be hosted live online and includes an audience Q&A. Instructions on how to join the conversation will be included in your event confirmation email. If you need additional assistance finding or joining the event, please email email@example.com.
This conversation does not promote, facilitate, or require the use of entheogens. This event and the views expressed by the presenter(s) are not a reflection of the views of California Institute of Integral Studies (CIIS), its Center for Psychedelic Therapies and Research, or the individuals employed by CIIS.
Rick Doblin, PhD, is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.